MX2022012990A - Process for generating genetically engineered autologous t cells. - Google Patents

Process for generating genetically engineered autologous t cells.

Info

Publication number
MX2022012990A
MX2022012990A MX2022012990A MX2022012990A MX2022012990A MX 2022012990 A MX2022012990 A MX 2022012990A MX 2022012990 A MX2022012990 A MX 2022012990A MX 2022012990 A MX2022012990 A MX 2022012990A MX 2022012990 A MX2022012990 A MX 2022012990A
Authority
MX
Mexico
Prior art keywords
cells
genetically engineered
generating genetically
engineered autologous
autologous
Prior art date
Application number
MX2022012990A
Other languages
Spanish (es)
Inventor
Yijun Liu
Kathryn A Henckels
Carlos Arbelaez
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2022012990A publication Critical patent/MX2022012990A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to production of autologous genetically engineered T cells for use in cell therapy applications.
MX2022012990A 2020-04-15 2020-04-15 Process for generating genetically engineered autologous t cells. MX2022012990A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2020/028192 WO2021211104A1 (en) 2020-04-15 2020-04-15 Process for generating genetically engineered autologous t cells

Publications (1)

Publication Number Publication Date
MX2022012990A true MX2022012990A (en) 2023-01-11

Family

ID=70476574

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012990A MX2022012990A (en) 2020-04-15 2020-04-15 Process for generating genetically engineered autologous t cells.

Country Status (6)

Country Link
EP (1) EP4135724A1 (en)
JP (1) JP2023522642A (en)
AU (1) AU2020442490A1 (en)
CA (1) CA3180143A1 (en)
MX (1) MX2022012990A (en)
WO (1) WO2021211104A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210324333A1 (en) * 2020-04-15 2021-10-21 Amgen Inc. Method for enhancing production of genetically engineered autologous t cells
AU2021410689A1 (en) 2020-12-22 2023-07-06 Amgen Inc. Mage-b2-specific t-cell receptors
EP4453016A1 (en) 2021-12-21 2024-10-30 Amgen Inc. Dcaf4l2-specific t-cell receptors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US7572631B2 (en) * 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
WO2015120096A2 (en) * 2014-02-04 2015-08-13 Marc Better Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof
GB201509202D0 (en) * 2015-05-28 2015-07-15 Ge Healthcare Bio Sciences Ab Semi-static cell culture
US12053490B2 (en) * 2017-10-26 2024-08-06 St. Jude Children's Research Hospital, Inc. Methods and compositions for treating CD33+ cancers and improving in vivo persistence of chimeric antigen receptor T cells

Also Published As

Publication number Publication date
CA3180143A1 (en) 2021-10-21
WO2021211104A1 (en) 2021-10-21
EP4135724A1 (en) 2023-02-22
JP2023522642A (en) 2023-05-31
AU2020442490A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
MX2022012990A (en) Process for generating genetically engineered autologous t cells.
MX2018005274A (en) Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells.
NZ703137A (en) Cells for producing recombinant iduronate-2-sulfatase
MX2021005021A (en) Process for producing genetically engineered t cells.
MX2020000369A (en) Biological methods for preparing terpenes.
AU2018271755A1 (en) Method for culturing natural killer cell, using transformed T cell
MX2018013445A (en) Genetically engineered cells and methods of making the same.
PH12020550039A1 (en) Sialyltransferases and their use in producing sialylated oligosaccharides
MX2019006438A (en) Production of engineered cells for adoptive cell therapy.
BR112017017810A2 (en) Materials and methods for treatment of hemoglobinopathies
MY189819A (en) Genetically modified cells and uses thereof
MX2021001523A (en) Processes for generating engineered cells and compositions thereof.
MA40253A (en) Engineered cells for adoptive cell therapy
MX2020005908A (en) Process for producing a composition of engineered t cells.
EP2633036A4 (en) Differentiation methods for production of glial cell populations
MX2022002143A (en) Immune cells for adoptive cell therapies.
MX342995B (en) Methods of generating natural killer cells.
RU2014148136A (en) T-CELL COMPOSITIONS WITH LACK OF T-CELL RECEPTORS
GB2527254A (en) Benzylisoquinoline alkaloids (BIA) Producing microbes, and methods of making and using the same
MY172307A (en) Production of muconic acid from genetically engineered microorganisms
MX2021009554A (en) Production of viruses in cell culture.
MX2021009967A (en) Methods for producing autologous t cells useful to treat cancers and compositions thereof.
SG10201809452RA (en) Cell culture compositions with antioxidants and methods for polypeptide production
PH12014502870A1 (en) Method of producing recombinant iduronate-2-sulfatase
PH12018502061A1 (en) Differentiation of pluripotent stem cells to intestinal midgut endoderm cells